![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, December 13, 2013 5:54:41 AM
You have a promising treatment that has shown documented results against one of the nastiest forms of cancer (Merkel Cell) with ongoing clinical trials and soon expected results.
You have an Executive Director of a fortune 500 (57 or 58) leaving to come work for a little podunk upstart pharma wannabe. Probably being given a boat load of stock options in lieu of millions in cash.
The aforesaid makes a statement such as ...
"We stand at a transformational moment in oncology. I'm convinced that intralesional therapy with IL12 drives systemic anti-tumor immune responses and has the potential to augment immunomodulatory therapies such as anti-PD-1."
Just gives you a good feeling IMHO.
Most importantly let's hope for a viable treatment for the sufferers.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM